Equities

Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)59.92
  • Today's Change-0.02 / -0.03%
  • Shares traded720.79k
  • 1 Year change+72.98%
  • Beta2.1266
Data delayed at least 15 minutes, as of Nov 25 2024 20:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy2
Outperform8
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The 11 analysts offering 12 month price targets for Rhythm Pharmaceuticals Inc have a median target of 69.00, with a high estimate of 84.00 and a low estimate of 58.00. The median estimate represents a 15.15% increase from the last price of 59.92.
High40.2%84.00
Med15.2%69.00
Low-3.2%58.00

Earnings history & estimates in USD

On Nov 05, 2024, Rhythm Pharmaceuticals Inc reported 3rd quarter 2024 losses of -0.73 per share. This result exceeded the -0.81 consensus loss of the 11 analysts covering the company and exceeded last year's 3rd quarter results by 3.95%.
The next earnings announcement is expected on Feb 20, 2025.
Average growth rate-45.99%
Rhythm Pharmaceuticals Inc reported annual 2023 losses of -3.20 per share on Feb 22, 2024.
Average growth rate-16.22%
More ▼

Revenue history & estimates in USD

Rhythm Pharmaceuticals, Inc. had 3rd quarter 2024 revenues of 33.25m. This bettered the 32.52m consensus of the 10 analysts covering the company. This was 189.92% above the prior year's 3rd quarter results.
Average growth rate+10.29%
Rhythm Pharmaceuticals, Inc. had revenues for the full year 2023 of 77.43m. This was 227.56% above the prior year's results.
Average growth rate+292.34%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.